Table 2 Clinical trials using IDO inhibitors
From: Targeting the indoleamine 2,3-dioxygenase pathway in cancer
Drug | Phase | Mono or combo | Cancer | Clinical trial ID | Comments |
|---|---|---|---|---|---|
INCB 024360 | I | Mono | All | NCT01195311 | ASCO 2013 |
Ib/II | With ipilimumab | Melanoma | NCT01604889 | ASCO 2014/Recruiting | |
II | With MELITAC 12.1 | Melanoma | NCT01961115 | Recruiting | |
II | Mono | Ovary | NCT01685255 | Recruiting | |
II | Mono | MDS | NCT01822691 | Recruiting | |
Ib/II | With MK3475 | All/NSCLC | NCT02178722 | Recruiting | |
Ib/II | With CDX-1401, poly ICLC | Ovary | NCT02166905 | Recruiting | |
Pilot | Mono | Ovary (neoaduvant) | NCT02042430 | Recruiting | |
Indoximod (NLG2101) | I | Mono | All | NCT00739609 | ASCO 2012 |
Ib | With docetaxel | All | NCT01191216 | ASCO 2013 | |
Ib/II | With AD.p53 DC vaccine | All/breast | NCT01042535 | ASCO 2013/Recruiting | |
II | With docetaxel | Breast (HER2-) | NCT01792050 | Recruiting | |
II | Mono | Prostate | NCT01560923 | Recruiting | |
II | With sipuleucel-T | Prostate | NCT01560923 | Recruiting | |
Ib/II | With nab-paclitaxel, gemcitabine | Pancreas | NCT02077881 | Recruiting | |
Ib/II | With ipilimumab | Melanoma | NCT02073123 | Recruiting | |
Ib/II | With temozolomide | Brain | NCT02052648 | Recruiting | |
IDO peptide vaccine | I | With imiquimod, montanide | NSCLC | NCT01219348 | Iversen 2013 [78] |
Ib | With temozolomide | Melanoma | NCT01543464 | Recruiting | |
NLG919 | I | Mono | All | NCT02048709 | Recruiting |